IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection shows promise for kidney disease in early trial
Disease control Not yet recruitingThis study tests a new drug called CM313 in 106 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and helps control the disease. Participants must have had a kidney biopsy showing IgA nephropathy within the last 8 years and be on standard care.…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New drug aims to quiet kidney disease in 10 patients
Disease control Not yet recruitingThis early-phase study tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease. The main goal is to see if the drug can lower protein in the urine, a sign of kidney damage, after 99 days. Participants must have had a kidney biopsy confirming the disease and…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New study tracks Real-World impact of kidney disease drugs
Knowledge-focused Not yet recruitingThis study will follow 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient characteristics, treatment patterns, and health outcomes over 24 months. The goal is to better understand how t…
Matched conditions: IGA NEPHROPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 22, 2026 13:53 UTC